Newcastle Disease — Vaccine Production

  • Garry M. Cross
Part of the Developments in Veterinary Virology book series (DVVI, volume 8)


Newcastle disease (ND) is highly contagious, and attempts to control it by slaughter, sanitary measures and quarantine are often unsuccessful. In those instances when the disease either exceeds the capacity of an eradication authority to contain it, or when it becomes endemic, vaccination of flocks at risk is a highly effective method of control.


Newcastle Disease Test Batch Infectious Bursal Disease Virus Primary Seed Adventitious Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Australian Code of Good Manufacturing Practice for Therapeutic Goods — National Biological Standards Laboratory, Canberra, A.C.T., 1983Google Scholar
  2. 2.
    Australian Therapeutic Goods Act, 1966 — Therapeutic Goods Order No. 21 — General Standard for Live Avian Viral Vaccines. Australian Government Publishing Service, Canberra, A.C.T., 1986.Google Scholar
  3. 3.
    Australian Therapeutic Goods Standards Committee Subcommittee on Avian Vaccines — Draft General Standard for Inactivated Avian Viral Diseases — February 1986.Google Scholar
  4. 4.
    Code of Federal Regulations — Title 9 — Animals and Animal Products — Parts 1 to 199. Published by the Office of the Federal Register National Archives and Records Service General Services Administration. U.S. Government Printing Office Washington 1986Google Scholar
  5. 5.
    Specifications for the Production and Control of Avian Live Virus Vaccines, Ministry of Agriculture, Fisheries and Food, 1977.Google Scholar
  6. 6.
    Specifications for the Production and Control of Killed Infectious Bronchitis, Egg Drop Syndrome’76 and Newcastle Disease Vaccines, Ministry of Agriculture, Fisheries and Food, February, 1985.Google Scholar
  7. 7.
    World Health Organisation Technical Report Series No. 595. Immunological Adjuvants. World Health Organisation, Geneva, 1975, p. 3–40.Google Scholar
  8. 8.
    Australian Department of Health. Draft Guidelines for Manufacture and Quality of Therapeutic Goods produced by Recombinant D.N.A. Technology, March, 1986.Google Scholar

Copyright information

© Kluwer Academic Publishers 1988

Authors and Affiliations

  • Garry M. Cross
    • 1
  1. 1.Department of Veterinary Clinical StudiesUniversity of SydneyCamdenAustralia

Personalised recommendations